Over the last two decades, large-cap pharma has increasingly embraced inorganic growth as the primary tool for building their portfolios. However, the current model may no longer meet future growth ambitions. Revenue potential and R&D productivity are both declining, and we expect to see deal prices escalating again. In this webinar, we discuss recent research evaluating how innovation was sourced and the resulting historical success across the top 20 pharma companies between 2005 and 2021 and demonstrate how a balanced business development (BD) investment strategy across early- and late-stage can help pharma drive capital efficacy and build a sustainable portfolio.
During this webinar, we:
- Uncover potential pitfalls with current innovation model
- Identify opportunities to re-balance investment mix to optimize capital efficacy and long-term return
- Discuss how companies may think about embracing an “innovation constellation” model